Squamous Cell Carcinoma of Head and Neck

Oncology
11
Pipeline Programs
10
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
3
5
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
250%
Small Molecule
250%
+ 7 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
2 programs
2
LenvatinibPhase 2Small Molecule
bintrafusp alfaPhase 21 trial
Active Trials
NCT04428047TerminatedEst. Jan 2022
E
EisaiChina - Liaoning
1 program
1
LenvatinibPhase 2Small Molecule1 trial
Active Trials
NCT04428151Completed408Est. Oct 2025
Takeda
TakedaTOKYO, Japan
1 program
1
PanitumumabPhase 2Monoclonal Antibody
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
ZD6474Phase 21 trial
Active Trials
NCT00459043Completed30Est. Feb 2012
NKGEN Biotech
NKGEN BiotechCA - Santa Ana
1 program
1
AFM24Phase 1/21 trial
Active Trials
NCT05099549Terminated11Est. Sep 2023
Sanofi
SanofiPARIS, France
1 program
1
AlomfilimabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT03829501Terminated222Est. Oct 2024
Transgene
TransgeneFrance - Illkirch-Graffenstaden
1 program
1
TG4050Phase 1/21 trial
Active Trials
NCT04183166Active Not RecruitingEst. Dec 2031
Novartis
NovartisBASEL, Switzerland
1 program
1
BYL719Phase 11 trial
Active Trials
NCT02537223Completed9Est. Feb 2020
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
REGN6569Phase 11 trial
Active Trials
NCT04465487Terminated38Est. Feb 2025
Totus Medicines
Totus MedicinesCA - Emeryville
1 program
1
TOS-358Phase 11 trial
Active Trials
NCT05683418RecruitingEst. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Merck & Co.bintrafusp alfa
EisaiLenvatinib
AstraZenecaZD6474
NKGEN BiotechAFM24
TransgeneTG4050
SanofiAlomfilimab
Totus MedicinesTOS-358
RegeneronREGN6569
NovartisBYL719

Clinical Trials (9)

Total enrollment: 718 patients across 9 trials

NCT04428047Merck & Co.bintrafusp alfa

Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma

Start: Feb 2021Est. completion: Jan 2022
Phase 2Terminated
NCT04428151EisaiLenvatinib

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Start: Aug 2020Est. completion: Oct 2025408 patients
Phase 2Completed
NCT00459043AstraZenecaZD6474

Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck

Start: Mar 2007Est. completion: Feb 201230 patients
Phase 2Completed
NCT05099549NKGEN BiotechAFM24

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

Start: Nov 2021Est. completion: Sep 202311 patients
Phase 1/2Terminated
NCT04183166TransgeneTG4050

A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

Start: Dec 2019Est. completion: Dec 2031
Phase 1/2Active Not Recruiting
NCT03829501SanofiAlomfilimab

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Start: Jan 2019Est. completion: Oct 2024222 patients
Phase 1/2Terminated
NCT05683418Totus MedicinesTOS-358

A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors

Start: Feb 2023Est. completion: Dec 2026
Phase 1Recruiting
NCT04465487RegeneronREGN6569

Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

Start: Oct 2020Est. completion: Feb 202538 patients
Phase 1Terminated
NCT02537223NovartisBYL719

Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer

Start: Sep 2015Est. completion: Feb 20209 patients
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
6m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
6m ago

Office Administrator

SystImmune
6m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
17m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
20m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
20m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 718 patients
10 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)